Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a ...
The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...
The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...
Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...
Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the ...
Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.
"If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who currently ...